NMN Dosage: What Human Trials Have Actually Used
NMN arrived with unusually loud claims and unusually little human data. The animal work is genuinely interesting; the human trials are small, short, and far more modest than the marketing built on top of them.
Published human studies of nicotinamide mononucleotide have generally used between 250 mg and 1,250 mg per day, over periods of roughly 8 to 12 weeks, in small samples. A study in prediabetic women used 250 mg daily and reported an improvement in muscle insulin sensitivity, and a Japanese dose-escalation study administered single oral doses up to 500 mg without serious adverse effects. There is no established requirement, no long-term human safety data, and the FDA has taken the position that NMN is excluded from the dietary supplement definition because it was authorised for investigation as a drug.
NMN amounts reported in published human studies
| Use case | Amount reported in sources | What to know |
|---|---|---|
| Muscle insulin sensitivity in prediabetic women | 250 mg per day for 10 weeks | Randomised, placebo-controlled trial published in Science reporting improved muscle insulin sensitivity. Source |
| Single-dose safety and pharmacokinetics | Single oral doses of 100, 250 and 500 mg | Dose-escalation study in healthy Japanese men reporting no serious adverse events at the doses tested. Source |
| Longer supplementation studies | Commonly 300–900 mg per day over 8–12 weeks | Small randomised trials have tested a range of daily amounts with varying endpoints and inconsistent results. Source |
| US regulatory status | Excluded from the dietary supplement definition per FDA | FDA's ingredient directory records the agency's position on NMN following prior drug investigation authorisation. Source |
Figures are amounts reported in the cited sources, not a personal recommendation. Your own amount depends on your health, medicines and blood work.
What NMN is supposed to do
Nicotinamide adenine dinucleotide, NAD+, is a coenzyme every cell uses in energy metabolism and in the activity of enzymes involved in DNA repair and cellular stress responses. Tissue NAD+ levels decline with age in animal models, and that observation is the entire foundation of the NAD+ precursor supplement category.
NMN is one step away from NAD+ in the salvage pathway; nicotinamide riboside is another precursor sold on the same logic. Both raise blood NAD+ metabolite markers in humans, which is a measurable and repeatable finding.
Raising a biomarker is not the same as producing a clinical outcome. The gap between 'NAD+ metabolites went up' and 'people aged more slowly' is where nearly all of the disagreement in this field lives.
- NAD+ falls with age in animal models
- NMN raises NAD+ metabolite markers in human blood
- Marker change is established; outcome change largely is not
- Nicotinamide riboside is a parallel precursor with the same debate
The human trials that exist
The most-cited human result is a 2021 randomised placebo-controlled trial published in Science, which gave 250 mg of NMN daily for ten weeks to postmenopausal prediabetic women and reported improved skeletal muscle insulin sensitivity relative to placebo.
That trial had 25 participants. Its authors described the result as a foundation for larger studies, not as evidence for a general anti-ageing effect, and secondary measures such as body composition and blood pressure did not differ.
A separate Japanese dose-escalation study administered single doses of up to 500 mg to healthy men and reported that they were safely metabolised without serious adverse effects, with changes in bilirubin and some other markers remaining within normal ranges. That is a safety and pharmacokinetics study, not an efficacy one.
Why the dose range is so wide
Commercial products span roughly 125 mg to 1,000 mg per capsule, and daily amounts recommended on labels vary by an order of magnitude. That variation reflects an absence of dose-finding trials rather than tailored evidence.
Where trials have compared amounts, they have generally been comparing safety and biomarker response rather than clinical benefit, so there is no published basis for saying that 900 mg outperforms 250 mg on any outcome that matters to a person.
Sublingual, liposomal and enteric-coated formats add another layer of marketing claims. Absorption differences between formats have not been shown to translate into different results in humans.
The regulatory situation is unusual
The FDA has stated that NMN is excluded from the dietary supplement definition because it was authorised for investigation as a new drug before being marketed as a supplement. That position is recorded in the agency's dietary supplement ingredient directory.
Practically, this means products may disappear from major retailers or be relabelled, and it means NMN sits outside the normal supplement framework in the United States. Availability elsewhere varies by jurisdiction.
None of that is a safety finding. It is a statement about which regulatory box the ingredient belongs in, and it is being contested by industry.
What is genuinely unknown
Long-term safety in humans has not been established. Trials to date have run weeks to a few months in small groups, which cannot detect uncommon or slow-developing effects.
There is also an open theoretical question about NAD+ precursors and cancer, because rapidly dividing cells use NAD+ too. This has not been demonstrated as a clinical risk in humans, and it has not been ruled out either. People with a history of cancer should treat this as a specialist conversation.
For anyone weighing it up, the honest position is that NMN is an interesting compound with a real biological rationale, small supportive human data, no long-term safety record, and a price that assumes far more certainty than exists.
What the published studies found
Each entry below links straight to the paper or the health authority page so you can read the original rather than take our word for it.
- Yoshino M, Yoshino J, Kayser BD, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021.
Randomised, placebo-controlled trial in 25 postmenopausal prediabetic women
250 mg of NMN daily for 10 weeks was associated with improved skeletal muscle insulin sensitivity compared with placebo, while other metabolic measures did not differ significantly.
- Irie J, Inagaki E, Fujita M, et al. Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men. Endocr J. 2020.
Single-dose escalation study in healthy men
Single oral doses up to 500 mg were safely metabolised without serious adverse effects, with nicotinamide metabolite levels rising after administration.
- US Food and Drug Administration. Dietary Supplement Ingredient Directory.
Regulatory reference listing agency positions on specific ingredients
Records FDA's position that NMN is excluded from the dietary supplement definition following prior authorisation for investigation as a drug.
Side effects reported in the literature
Commonly reported
- Nausea or stomach discomfort reported anecdotally
- Headache
- Flushing, more commonly associated with high-dose niacin than with NMN
Serious, seek medical advice
- No long-term human safety data exist
- Unresolved theoretical questions about NAD+ precursors in people with a cancer history
- Uncertain product quality given the contested regulatory status
Summarised from Endocrine Journal 2020 single-dose safety study. Report anything unexpected to your own doctor or pharmacist.
Interactions to check with a pharmacist
| Medicine or condition | What sources report |
|---|---|
| Diabetes medicines | The main positive human trial measured insulin sensitivity, so glucose monitoring matters if you are treated for diabetes. Source |
| History of cancer | Open theoretical questions about NAD+ availability make this a specialist decision. Source |
| Other NAD+ precursors such as nicotinamide riboside or niacin | Stacking precursors has not been studied and can add flushing or nausea. Source |
This is not a complete interaction list. Check your own medicines with a pharmacist before combining anything.
This page is reference material, not medical advice. Supplements interact with prescription medicines and with each other. Talk to a doctor or pharmacist before starting anything, especially if you are pregnant, breastfeeding, managing a health condition or taking prescription medicine.
Frequently asked questions
How much NMN should I take per day?
Published human studies have used roughly 250 mg to 1,250 mg a day, and the trial that reported a positive metabolic result used 250 mg daily for ten weeks in 25 women. There is no dose-finding evidence showing that larger amounts work better.
Is 500 mg of NMN a good dose?
It sits within the range that has been administered in human studies, and a Japanese dose-escalation study gave single doses up to 500 mg without serious adverse effects. That establishes short-term tolerability, not benefit at that amount.
Does NMN actually work?
It reliably raises NAD+ metabolite markers in humans. Whether that produces meaningful clinical outcomes is unresolved — the strongest human result so far is improved muscle insulin sensitivity in a 25-person trial.
Is NMN banned in the US?
Not banned, but the FDA has stated it is excluded from the dietary supplement definition because it was authorised for drug investigation first. That affects how and where it can be sold rather than reflecting a safety recall.
NMN or NR — which is better?
Both are NAD+ precursors and both raise NAD+ metabolites in humans. There is no head-to-head clinical outcome evidence that establishes one as superior.
Is NMN safe long term?
Unknown. Human trials have run weeks to a few months in small samples, which cannot detect uncommon or slow-developing effects.
When should I take NMN?
Trials generally dosed once daily in the morning without a compelling timing rationale being tested. Timing is not an evidence-based lever here.
Keep reading
Sources
- Yoshino M, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372(6547):1224–1229.
- Irie J, et al. Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men. Endocr J. 2020;67(2):153–160.
- US Food and Drug Administration. Dietary Supplement Ingredient Directory.
Track your dose in DoseRoutine
Log what you actually take, get reminders at the right time and check interactions against everything else in your stack.
Sign up free →